A single dose, randomized, 5-period, balanced, crossover study to assess the relative bioavailability of three formulations and food effect on GSK364735 [S 364735] and pharmacokinetics following a double-blind, placebo controlled, repeat dose administration to healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2012
At a glance
- Drugs S 364735 (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 17 Dec 2006 New trial record.